Rare diseases, immense needs: J&J’s mission to change the landscape

Rare diseases may seem niche, but their impact is far from small. An estimated 7,000 rare diseases exist, collectively affecting a staggering 300 million people worldwide.  This immense burden of disease, coupled with a profound lack of treatment options, underscores the urgent need for innovation. “Actually, the total burden of disease and unmet medical need [for rare disease] is really high,” emphasizes Dr. Katie Abouzahr, vice president, autoantibody portfolio and maternal fetal disease area leader at Johnson and Johnson Innovative Medicine. In recognition of Rare Disease Day on February 29 in 2024, we spoke with Abouzahr to explore how Johnson & Johnson Innovative Medicine aims to tackle these challenges.

The profound scarcity of treatments for the thousands of known rare diseases drives Johnson & Johnson’s commitment to this area. Abouzahr highlights that many of these diseases still lack advanced therapies, emphasizing the “incred…

Read more
  • 0

How a J&J exec found her calling in autoantibody drug development

Katie Abouzahr

Dr. Katie Abouzahr’s career, which began in the wards of the UK’s National Health Service (NHS) before extending into management consulting, paved the way for her leadership of autoantibody and maternal fetal medicine programs at Johnson & Johnson. “It’s not a typical pharma executive’s straight line path,” she acknowledged. “Careers can often be jungle gyms as opposed to ladders that you climb one rung at a time. It’s always a mixture of opportunity, timing, serendipity, and persistence.”

Those qualities helped pave the way for her current focus on autoantibody-based conditions marked by high unmet need. Drawing on her experience across clinical medicine, consulting, and drug development, Abouzahr focuses on advancing medicines for autoimmune and autoantibody-driven diseases, which are marked by high unmet need. The broader immunology area is a central …

Read more
  • 0